Loading
Life sciences · Journal article
Frontiers in Oncology · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction Head and neck cancer is a disease with a tendency for recurrence and metastases even after treatment. Late detection leads to poor patient outcomes. One promising diagnostic tool is FDG-PET/CT which can detect both, morphological and metabolic evidence of malignant diseases. A common measure is SUVmax, the maximum standardized uptake value in a lesion. The objective of this study is to evaluate the prognostic value of post-treatment FDG-PET/CT in patients with head and neck squamous cell carcinoma (HNSCC), focusing on the association of SUVmax and scan timing with progression-free survival (PFS). Methods This retrospective study included 84 patients with HNSCC treated with definitive radiotherapy between 2016 and 2023 at a German university hospital. All patients underwent at least one post-radiotherapy FDG-PET/CT scan. All post radiation scans that were performed before or no later than one month after documented disease progression were included for prognostic analysis. SUVmax values were categorized into three groups: (1) physiological uptake (no suspicious lesion, no SUVmax value recorded, and radiological report consistent with post-therapeutic changes), (2) intermediate uptake (SUVmax >1 but <7.5), and (3) high uptake (SUVmax ≥7.5). PET/CT timing was stratified as early (≤3 months) or delayed (>3 months) after radiotherapy. Diagnostic performance metrics and survival outcomes were analyzed. Results A total of 88 post-treatment PET/CT scans were evaluated. Mean follow up was 27.7 months. Disease progression occurred in 33 patients and 10 patients died during follow-up. SUVmax ≥7.5 was significantly associated with shorter PFS (p < 0.05). Intermediate SUVmax values also predicted increased progression risk compared to physiological uptake. The optimal diagnostic performance was achieved with delayed PET/CT (>3 months), particularly using a low SUVmax threshold (>1), which yielded high sensitivity (90.9%) and negative predictive value (88.9%). Multivariate analysis confirmed SUVmax as an independent predictor of PFS (HR: 1.21; 95% CI: 1.11-1.32; p < 0.001), alongside male sex and oral cavity primary site. Conclusion Post-treatment FDG-PET/CT is a valuable prognostic tool in HNSCC follow-up. SUVmax, especially when evaluated after three months, is predictive of disease progression. Integrating PET/CT into routine surveillance may improve risk stratification and inform tailored follow-up intensity.